| Kevin Charles Gorman |
Kevin Charles Gorman is the founder of Neurocrine Biosciences, Inc., which was founded in 1992. He holds the title of Chief Executive Officer & Director at Neurocrine Biosciences, Inc. starting in 2017. Dr. Gorman is currently working as an Independent Director at Xencor, Inc. since 2017. In the past, he worked as a Principal at Avalon Medical Partners LP from 1990 to 1993. Dr. Gorman has an MBA and a doctorate from the University of California, Los Angeles. |
| Ingrid Delaet |
Ingrid Delaet is currently the Chief Regulatory Officer at Neurocrine Biosciences, Inc. She previously worked as the Senior Vice President-Regulatory Affairs at Intercept Pharmaceuticals, Inc. from 2016 to 2021. Dr. Delaet holds graduate and doctorate degrees from Université Libre de Bruxelles. |
| Dimitri E. Grigoriadis |
Dimitri E. Grigoriadis is currently the Chief Research Officer at Neurocrine Biosciences, Inc. He is also a Member of the International Society of Psychoneuroendocrinology. Previously, he worked as a Senior Scientist-Neuroscience Group at DuPont Pharmaceuticals Co. from 1990 to 1993. Dr. Grigoriadis completed his undergraduate degree at the University of Guelph and his graduate and doctorate degrees at the University of Toronto. |
| Bill Wilson |
Bill Wilson currently works at Neurocrine Biosciences, Inc., as Vice President-Information Technology & Operations from 2004 and CIO Executive Council, as Founding Member. |
| Eric S. Benevich |
Eric S. Benevich is currently the Chief Commercial Officer at Neurocrine Biosciences, Inc. Prior to this, he worked as the Vice President of Communications & Marketing at Avanir Pharmaceuticals, Inc. from 2011 to 2015 and as the Senior Director of Marketing at Peninsula Pharmaceuticals, Inc. He completed his undergraduate degree at Washington State University. |
| Kyle W. Gano |
Kyle W. Gano is currently the Chief Business Development & Strategy Officer at Neurocrine Biosciences, Inc. He started this position in 2020. Prior to his current role, he obtained an undergraduate degree from the University of Washington in 1996. He then pursued further education and earned an MBA and a doctorate from the University of California, Los Angeles. Additionally, he completed his undergraduate studies at the University of Oregon. |
| Matthew C. Abernethy |
Matthew C. Abernethy currently works at BIOCOM, as Director from 2019 and Neurocrine Biosciences, Inc., as Chief Financial Officer from 2017. Mr. Abernethy also formerly worked at Biomet, Inc., as Treasurer, Zimmer Biomet Holdings, Inc., as Treasurer & Vice President-Investor Relations from 2009 to 2017, Biomet Orthopedics LLC, as Vice President-Finance from 2009 to 2015, and Zimmer US, Inc., as Treasurer from 2009 to 2017. Mr. Abernethy received his undergraduate degree from Grace College & Seminary and Masters Business Admin degree from The University of Chicago. |
| Eiry W. Roberts |
Eiry W. Roberts is an Independent Director at Amicus Therapeutics, Inc., Chief Medical Officer at Neurocrine Biosciences, Inc., and a Member of the Healthcare Businesswomens Association. Previously, Roberts was the Director of the Indianapolis Children's Choir, Vice President-Clinical Pharmacology & MD at Eli Lilly & Co., and a Member of the Indiana Health Industry Forum. Roberts also served as a Trustee of St. Richard’s Episcopal School Foundation, Inc. Roberts earned a doctorate degree from the University of London in 1987. |
| David W. Boyer |
David W. Boyer is currently the Chief Corporate Affairs Officer at Neurocrine Biosciences, Inc. Previously, he worked as the Principal & Head-Health & Lifesciences Practice at BGR Holding LLC. He completed his undergraduate degree at Georgetown University. |
| Jude Onyia |
Jude Onyia is currently the Director at Voyager Therapeutics, Inc. and the Chief Scientific Officer at Neurocrine Biosciences, Inc. Prior to his current roles, he worked at Eli Lilly & Co. for 26 years, where he held the position of Vice President-Biotechnology Discovery Research from 2014 to 2021. He also briefly served as the Chief Scientific Officer at Capsida Biotherapeutics, Inc. in 2021. Onyia received his undergraduate degree from The State University of New York and his doctorate from the State University of New York at Downstate Medical Center. |
| Haig P. Bozigian |
Haig P. Bozigian is currently the Chief Development Officer at Neurocrine Biosciences, Inc. He started this position in 2006. Prior to his current role, he worked as the Director of Pharmaceutical Development at ProCyte Corp. and as the Associate Director of Pharmacokinetics at Sphinx Pharmaceuticals Corp. Bozigian holds a doctorate degree from the University of Arizona, an undergraduate degree from the University of Massachusetts, and a graduate degree from the University of Nebraska Medical Center. |
| William H. Rastetter |
William H. Rastetter is the founder of Apoptos, Inc. (founded in 2007), Receptos LLC (founded in 2009), and GRAIL LLC (founded in 2015). He held the title of Chairman & Chief Executive Officer at Apoptos, Inc. in 2009, Executive Chairman at Receptos LLC from 2010 to 2015, and Director at GRAIL LLC from 2018 to 2021. His current job(s) include Chairman at Neurocrine Biosciences, Inc. since 2010, Chairman at Fate Therapeutics, Inc. since 2011, Chairman at Daré Bioscience, Inc. since 2014, Chairman at San Diego Squared, Director at CONNECT, Independent Director at Regulus Therapeutics, Inc. since 2013, Director at Entos, Inc., Advisor at Leerink Partners LLC, Trustee at California Institute of Technology, and Advisor at IIF Management Co. LLC. His former job(s) include Chairman & Chief Executive Officer at Celgene Corp. from 2009 to 2015, Chairman & Chief Executive Officer at IDEC Pharmaceuticals Corp. from 1986 to 2003, Executive Chairman at Biogen, Inc. from 1986 to 2005, Chairman at Illumina, Inc. from 1998 to 2016, Chairman at Cerulean Pharma, Inc. from 2014 to 2017, Executive Chairman at Biogen Idec, Inc. (North Carolina) from 2003 to 2005, Director-Corporate Ventures at Genentech, Inc. from 1982 to 1986, Partner at Venrock Associates from 2006 to 2013, and Faculty Member at Harvard University. He also served as an Associate Professor at Massachusetts Institute of Technology from 1975 to 1982 and is a Board of Trustees member at MPRD Ltd.His education includes graduate and doctorate degrees from Harvard University and an undergraduate degree from Massachusetts Institute of Technology. |
| Darin M. Lippoldt |
Darin M. Lippoldt is currently the Secretary & Chief Legal Officer at Neurocrine Biosciences, Inc. He previously worked as the Associate General Counsel at Amylin Pharmaceuticals, Inc. from 2003 to 2010 and as the Secretary, Chief Compliance Officer & Executive VP at Philips Image Guided Therapy Corp. from 2013 to 2014. Lippoldt received his undergraduate and graduate degrees from St. Mary's University in 1987 and 1995, respectively. |
| Julie S. Cooke |
Julie S. Cooke is currently the Chief Human Resources Officer at Neurocrine Biosciences, Inc. She previously worked as a Compensation Director at Pepsi-Cola North America, Director-Human Resources at Gateway Computers, Vice President-Human Resources at SGX Pharmaceuticals, Inc., Senior Vice President-Human Resources at Sanford Burnham Prebys Medical Discovery Institute, and Vice President-Human Resources at Life Technologies Corp. Cooke received her undergraduate degree from The Colorado College in 1988. |
| George J. Morrow |
George J. Morrow is an Independent Director at Neurocrine Biosciences, Inc. since 2015 and at Align Technology, Inc. since 2006. He previously served as the President, Chief Executive Officer & Director at Glaxo Wellcome, Inc. from 1993 to 2001. He also held positions as an Independent Director at Safeway, Inc. from 2013 to 2015, at Vical, Inc. from 2012 to 2019, at Human Genome Sciences, Inc. in 2011, and at Otonomy, Inc. from 2015 to 2018. Additionally, he served as a Director at Johns Hopkins Bloomberg School of Public Health, The Fuqua School of Business, and National Commerce Bank. Mr. Morrow's former roles also include being the Executive VP-Global Commercial Operations at Amgen, Inc. from 2003 to 2011 and Vice President-Marketing at Merck & Co., Inc. from 1981 to 1992. He holds a graduate degree from Bryn Mawr College, an undergraduate degree from Long Island University, and MBA degrees from The Fuqua School of Business and Duke University. |
| Christine A. Poon |
Christine A. Poon currently works at Royal Philips Electronics USA, as Vice Chairman, The Prudential Variable Contract Real Property Account, as Director, Regeneron Pharmaceuticals, Inc., as Lead Independent Director, The Sherwin-Williams Co., as Independent Director from 2014, Neurocrine Biosciences, Inc., as Independent Director from 2023, Prudential Financial, Inc., as Independent Director from 2023, Crane Group Co., as Director from 2014, and The Prudential Insurance Company of America, Inc., as Director from 2006. Ms. Poon also formerly worked at Johnson & Johnson, as Vice Chairman from 2005 to 2009, Koninklijke Philips NV, as Vice Chairman-Supervisory Board & Secretary from 2009 to 2021, The Fox Chase Cancer Center, as Director, Decibel Therapeutics, Inc., as Independent Director from 2019 to 2021, Bristol Myers Squibb Co., as President-International Medicines from 1997 to 2000, and Fisher College of Business, as Professor from 2014 to 2015. Ms. Poon received her Masters Business Admin degree from Boston University, undergraduate degree from Northwestern University, and graduate degree from St. Louis University. |
| Johanna Mercier |
Johanna Mercier is currently an Independent Director at Neurocrine Biosciences, Inc., a Director at Robert Wood Johnson University Hospital, Inc., a Director at Arcus Biosciences, Inc., a Director at Leonard D Schaeffer Center For Health Policy & Economics, a Chief Commercial Officer at Gilead Sciences, Inc., and a Member at World 50, Inc. She previously worked as the President-US Commercial at Bristol Myers Squibb Co. Ms. Mercier holds an MBA from Concordia University and an undergraduate degree from the University of Montréal. |
| Leslie V. Norwalk |
Leslie V. Norwalk is currently serving as an Independent Director at Neurocrine Biosciences, Inc., ModivCare, Inc., Globus Medical, Inc., Linkwell Health, Inc., Healtheo360 LLC, Arvinas Operations, Inc., The Institute for Health Technology Studies, CareCentrix, Inc., Quanta Dialysis Technologies Ltd., Santé Pediatric Services, Adobe Healthcare, Inc., Arvinas, Inc., MedCircle, Inc., ProgenyHealth LLC, Grenova, Inc., National Health Advisors, Epstein Becker & Green PC, Epsilon Health Investors LLC, and Koa Health. She has previously served as a Director at MTS Medication Technologies, Inc., Magellan Health, Inc., Endologix LLC, Centene Corp., NuVasive, Inc., Philips Image Guided Therapy Corp., Visiant Holdings, Inc., WhiteGlove Health, Inc., HealthPlanOne LLC, The Broadlane Group, Inc., Guardian Healthcare Group, Inc., Press Ganey Associates, Preferred Care Partners, Inc., Sound Inpatient Physicians, Inc., STARUS Medical Group, Inc., and Press Ganey Associates LLC. She was also the Chief Operating Officer & Deputy Administrator at Centers for Medicare & Medicaid Services (US) from 2001 to 2007. Norwalk holds an undergraduate degree from Wellesley College and a graduate degree from George Mason University School of Law. |
| Richard F. Pops |
Richard F. Pops is the founder of Sirtris Pharmaceuticals, Inc. (founded in 2004) and held the title of Director. He is currently the Chairman & Chief Executive Officer at Alkermes, Inc. (since 1991) and Alkermes Plc (since 1991). He is also an Independent Director at Neurocrine Biosciences, Inc. (since 1998) and a Director at the Biotechnology Innovation Organization and Pharmaceutical Research & Manufacturers of America. Mr. Pops has previously served as a Director at Expressive Constructs, Inc. and Reliant Pharmaceuticals LLC. He was the Lead Independent Director at Acceleron Pharma, Inc. from 2004 to 2019 and a Director at CombinatoRx, Inc. from 2001 to 2009. He has also held positions as a Director at the New England Healthcare Institute, Epizyme, Inc., The National Health Council, and Zalicus, Inc. Mr. Pops was a Member-Board Fellow at Harvard Medical School from 2002 to 2012 and currently serves as a Strategic Advisor at Longwood Fund Management LLC. He completed his undergraduate degree at Stanford University in 1983. |
| Gary A. Lyons |
Gary A. Lyons founded GL Biomed in 2008, where he is working as President from 2008. Mr. Lyons also currently works at Travere Therapeutics, Inc., as Chairman from 2016, Neurocrine Biosciences, Inc., as Independent Director from 2008, Rigel Pharmaceuticals, Inc., as Independent Director, and Healthcare Royalty Management LLC, as advisors and Board Member from 2018. Mr. Lyons also formerly worked at NeurogesX, Inc., as Executive Chairman from 2011 to 2013, Poniard Pharmaceuticals, Inc., as Director from 2009 to 2012, Vical, Inc., as Independent Director from 1997 to 2019, IntraBiotics Pharmaceuticals, Inc., as Director, Humanigen, Inc., as Independent Director from 2012 to 2015, Abbott Biotherapeutics Corp., as Director from 2008 to 2010, American Hospital Supply Corp., as Sales Director-American Critical Care from 1973 to 1983, Plus Therapeutics, Inc., as Independent Director from 2014 to 2019, PDL BioPharma, Inc., as Director in 2008, Eledon Pharmaceuticals, Inc., as Independent Director from 2017 to 2023, Fresh Tracks Therapeutics, Inc., as Independent Director from 1997 to 2023, Kalobios Pharmaceuticals, Inc., as Director, and Genentech, Inc., as Vice President-Business Development & Sales from 1983 to 1993. Mr. Lyons received his undergraduate degree in 1973 from the University of New Hampshire and Masters Business Admin degree in 1983 from Kellogg School of Management. |
| Shalini Sharp |
Shalini Sharp is currently the Chairman at Mahzi Therapeutics, Inc. She is also an Independent Director at Neurocrine Biosciences, Inc., Global Alliance for TB Drug Development, and Organon & Co. Additionally, she serves as a Director at Alameda County Community Food Bank and Treasurer & Vice President at Dimension Therapeutics, Inc. In her former roles, Ms. Sharp served as the Chief Executive Officer at Elan Corp. Plc from 2001 to 2003. She was an Independent Director at Agenus, Inc. from 2003 to 2018, Array BioPharma, Inc. from 2017 to 2019, Precision BioSciences, Inc. from 2018 to 2022, Sutro Biopharma, Inc. from 2018 to 2023, and Mirati Therapeutics, Inc. from 2021 to 2024. She also served as a Director at Panacea Acquisition Corp. from 2020 to 2021 and Chief of Staff at Elan Pharmaceuticals LLC from 1998 to 2003. Furthermore, she was the Chief Financial Officer & Senior VP-Finance at Ultragenyx Pharmaceutical, Inc. from 2012 to 2020. Ms. Sharp holds an MBA from Harvard Business School and an undergraduate degree from Harvard College. |
| Stephen A. Sherwin |
Stephen A. Sherwin was the founder of Ceregene, Inc. (founded in 2001) where he served as Chairman from 2001 to 2013. He is also the founder of Abgenix, Inc. Dr. Sherwin's current job positions include Lead Independent Director at Neurocrine Biosciences, Inc. (since 1999), Independent Director at Biogen, Inc. (since 2010), Director at Avertix Medical Systems, Inc., Director at Rheos Medicines, Inc., Independent Director at BioPlus Acquisition Corp. (since 2021), Professor at The University of California, San Francisco, Member of the American Society of Clinical Oncology, Inc., Member of the American Association for Cancer Research, Advisory partner at Third Rock Ventures LLC (since 2016), Member-Supervisory Board at Biogen GmbH (since 2010), and Clinical Professor at the University of California. Dr. Sherwin's former job positions include Chairman & Chief Executive Officer at Cell Genesys, Inc. (1990-2009), Chairman at Biotechnology Innovation Organization (2001-2014), Independent Director at Vical, Inc. (2013-2015), Director at ANI Pharmaceuticals, Inc. (2009-2013), Independent Director at Rigel Pharmaceuticals, Inc. (2000-2017), Independent Director at Aduro BioTech, Inc. (2015-2020), Director at Biogen Idec New Ventures, Inc., Independent Director at Verastem, Inc. (2013-2016), Independent Director at BioNTech US, Inc. (2015-2020), and Vice President-Clinical Research at Genentech, Inc. (1983-1990). Dr. Sherwin's education includes an undergraduate degree from Yale University and a doctorate degree from Harvard Medical School. Dr. Sherwin is also the founder of Abgenix, Inc... |
